Here are five quick key notes:
1. The five analysts gave the company an average broker rating score of 1.00 — a “strong buy.”
2. The 12-month consensus target price was set at $26.33.
3. The analysts expect the company to post $0.23 earnings per share for the current quarter.
4. K2M traded down 0.36 percent on Tuesday, hitting $24.85.
5. The market cap is $985.43 million.
Northland Securities also recently initiated coverage on the company, setting the price target at $31 and rating the company as “outperform.”
More articles on orthopedic devices:
6 key trends in the North American joint reconstruction market
Orchid opens new India plant—5 things to know
8 trends in the China orthopedic instrument market
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.